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regularly and available free on the internet. It provides 
summaries o f the disease that are written by experts 
and contact details o f patient support groups. The 
website is widely used by healthcare professionals, but 
glossaries are also available, to explain genetic term s or 
medical terminology, with links to reputable medical 
sites on the internet. A  similar directory and website 
provided by the National O rganisation for Rare Disor­
ders (www.rarediseases.org) provides inform ation and 
links with patients’ support groups in N orth America.2
D octors recom m ending a support group will find 
that it is very helpful for many families, who will come 
in contact with o ther families and share their problems. 
However, the encounter can be stressful for patients 
whose condition was diagnosed recently and for their 
families as it may bring them  face to face with patients 
who have severe manifestations o f the disease. Doctors 
should first review the inform ation given by the 
patients’ group and discuss this problem  with families 
before recom m ending the resource.
Patients without a diagnosis cannot be helped by 
this resource as support groups aim to help those with 
specific diseases. So what about children in whom 
there clearly is some form of a rare syndrome, yet no 
diagnosis has been made? They are no t left without 
support as there is a group—Syndromes without a 
Name—for undiagnosed syndromes listed on the 
directory.
If the rare disease is caused by a single gene dis­
order an excellent resource for inform ation is provided 
by the National Institutes for Health in the United 
States. O nline Mendelian Inheritance in Man 
(www.ncbi.nlm.nih.gov/omim/) provides detailed clini­
cal reviews for 14 184 single gene disorders, together
with the latest genetic research. The inform ation 
provided on this site is being updated continually and 
is reviewed by experts. The site also provides a 
comprehensive list o f references, which can then be 
accessed through a link to PubMed. More adventurous 
and curious users may explore the links to genetic 
databases in the fruit fly, mouse, and o ther animal spe­
cies. This internet resource is a practical example o f 
how the hum an genom e m apping project is dissemi­
nating genetic inform ation and can benefit physicians 
from various specialties.
W hat is rare for the generalist may be com m on for 
the specialist. Regional genetic services cover popula­
tions o f around three million and therefore develop 
clinical expertise in many rare inherited disorders. 
Direct contact with o r referral to the clinical genetic 
staff will answer specific questions and provide m ore 
support and access to diagnostic testing. A  list o f the 
regional genetic centres is provided on Contact a 
Family’s website.
Where textbooks have no t provided an answer 
about a rare inherited disorder many answers are now 
available with relative ease o f access beyond textbooks.
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Not so benign intracranial hypertension
Condition needs to be diagnosed before patients develop visual symptoms
r p  *lal a com m on antibiotic, doxycycline, used to 
treat malaria, acne, and o ther infections could 
cause increased intracranial pressure is no t a 
recent revelation.' O ther tetracyclic antibiotics such as 
minocycline and tetracycline have caused intracranial 
hypertension.
Benign intracranial hypertension is a syndrome of 
signs and symptoms o f increased intracranial pressure 
without causative lesions on images obtained by 
magnetic resonance imaging o r com puted tom ogra­
phy.2 The disorder is controversial from its nam e to its 
putative pathophysiology, but it should be considered 
when anyone taking doxycycline begins to complain o f 
a new headache.
The first controversy surrounding the disorder is the 
name—benign intracranial hypertension. For over 100 
years the condition has been known as pseudotum our 
cerebri o r benign intracranial hypertension.3 Corbett 
and Thompson, following the lead of Buchheit, m ade a 
plea to replace “benign” with “idiopathic,”1 to set apart 
the idiopathic form of increased intracranial pressure 
from symptomatic forms, and to dispel the notion that 
the condition is totally benign.
W hat to call this syndrome is far from settled, but at 
present we diagnose the prim ary o r idiopathic form in 
individuals in whom no cause can be found after care­
ful questioning and clinical evaluation. The secondary 
forms o f intracranial pressure should be characterised 
as intracranial hypertension due to venous thrombosis, 
o r intracranial hypertension due to medication, such as 
doxycycline.
The o ther m ajor controversy concerns the cause o f 
intracranial hypertension. O ne group posit that all 
forms o f intracranial hypertension, idiopathic and sec­
ondary, are due to venous occlusion, o r venous hyper­
tension.’ However, others have shown that changes in 
the venous sinuses including venous hypertension may 
be secondary to the intracranial hypertension itself. 
King showed that if pressure o f cerebrospinal fluid is 
reduced the venous hypertension disappears."
How doxycycline causes intracranial hypertension 
is no t known; however, case reports abound o f 
increased intracranial pressure associated with drugs 
including tetracycline,' minocycline'’ and doxycycline.'1 
Proposed mechanism s by which “cyclines” (tetracy­
cline, doxycycline, minocycline) cause intracranial
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hypertension include the drugs' interference with the 
energy dependent absorption mechanism by affecting 
cyclic adenosine m onophosphate at the arachnoid 
granulations.'' A lthough no clear genetic link exists to 
increased intracranial pressure, a genetic predisposi­
tion was proposed when dizygotic twin sisters 
developed the disorder. Both were taking tetracycline 
for acne. O ne was symptomatic with papilloedem a, 
headache, and intracranial hypertension, while the 
o ther was found to have asymptomatic papilloedem a 
after her twin had received her diagnosis.1" Most of 
what we know about benign intracranial hypertension 
concerns the idiopathic form. M ore com m on than 
previously recognised, idiopathic intracranial hyper­
tension occurs in 10-20/100 000 obese women. This 
m eans that idiopathic intracranial hypertension is as 
com m on am ong obese women as multiple sclerosis. 
The disorder affects women (7:1), who present with 
symptoms o f intracranial hypertension (headache, 
diplopia, whooshing noises in the head) and signs of 
intracranial hypertension (papilloedema, palsy of the 
sixth cranial nerve). Ninety per cent o f the patients 
are obese.3
In contrast, intracranial hypertension due to the 
tetracycline antibiotics (including doxycycline) occurs 
in both sexes, at alm ost any age, and without con­
com itant obesity. The symptoms and signs o f intracra­
nial hypertension, however, are the same. How quickly 
a person develops intracranial hypertension after 
ingesting doxycycline is unknown, but in the largest 
review of intracranial hypertension induced by m ino­
cycline, som e participants had used the drug for up to 
a year before developing symptoms whereas others 
becam e symptomatic within two weeks." Some dispute 
w hether tetracyclines cause intracranial hypertension 
at all since so many individuals are treated with the 
drug every year w ithout developing intracranial 
hypertension. However, individual cases have been 
reported  where stopping the drug resolved symptoms 
and signs of intracranial hypertension, and restart­
ing the drug brought recurrence of intracranial 
hypertension."
No matter whether the disorder is idiopathic or sec­
ondary, it is known to be anything but benign. Corbett et 
al found that idiopathic intracranial hypertension often 
persists up to 41 years after the initial diagnosis, and that 
over 25% of patients have severe visual loss.12 Patients 
with secondary forms of intracranial hypertension such 
as those using doxycycline are also no t im m une to visual 
loss. In 12 patients with minocycline induced intracra­
nial hypertension 25% had notable visual field loss.'' 
Therefore, patients who complain of headache after 
using doxycycline should be examined carefully, includ­
ing their visual acuity, and formal testing of the visual 
fields. Funduscopy after dilating the pupils to look for 
papilloedema is mandatory.
Treatm ent o f the prim ary and secondary forms of 
intracranial hypertension is similar—reduce intracra­
nial hypertension. W hile there are no random ised 
controlled trials to guide the choice of treatm ent m ost 
practitioners recom m end acetazolamide and weight 
loss to treat prim ary idiopathic hypertension. In the
secondary forms, correcting the underlying m ech­
anism, for example, treating the venous thrombosis, or 
stopping the causative m edication is indicated. If 
visual loss progresses despite optimal medical therapy 
(usually acetazolamide, methazolam ide, o r furosemide 
(frusemide) in adequate doses), consideration of optic 
nerve sheath fenestration or lum bar peritoneal shunt 
is w arranted to prevent further visual loss.3 Risk 
factors for visual loss include a delay in diagnosis due 
to failure to diagnose the disorder, inadequate 
treatm ent, and delayed treatm ent.3 The outcom e of 
increased intracranial pressure due to doxycyclines is 
generally good if recognised early, before vision has 
been affected seriously.
Despite the many controversies, intracranial 
hypertension due to use of doxycycline does occur. 
Practitioners prescribing the tetracyclic antibiotics 
should be aware of the syndrom e of increased intrac­
ranial pressure, and pay particular attention to the 
ocular fundus for papilloedem a. A ppropriate referral 
for visual testing including visual fields should be 
m ade, and treatm ent directed at stopping the drug, 
and instituting symptomatic treatm ent that lowers the 
intracranial pressure.
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Correction
Tobacco, coffee, and Parkinson's disease
An error occurred in the authors’ names in this editorial 
(15 March, p 562). The name of the second author should 
have been Catharine Gale, not Chris Gale, and she should 
have been listed as the first author. We apologise for this 
editorial error.
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